Biohaven Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Biohaven Ltd.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-195.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 88% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-105.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 84% of Healthcare companies in United States.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 65% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 75% of Healthcare companies in United States.
Tangible Net Worth Ratio
62%Of every $100 of net worth, $62 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 53% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Biohaven Ltd. made a loss over the last year. Biohaven Ltd. owes $0.97 for every $1 it owns. Biohaven Ltd. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBiohaven Ltd. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
181.54The share price is 181.54 times Biohaven Ltd.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$2.2 BThe total market value of all of Biohaven Ltd.'s shares at today's price (share price × number of shares), larger than 76% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$12 MWhat Biohaven Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.08Net worth divided by the number of shares. The share price of $14.69 is 181.5 times this, which is the P/B above.
Return on equity (ROE)
-799.5%Biohaven Ltd. lost 799.5% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
Owes vs Owns
0.97×Biohaven Ltd. owes $0.97 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Dividend yield
NoneBiohaven Ltd. does not currently pay a dividend.
Profit growth
LossBiohaven Ltd. made a loss in each of the last two years.
Cash vs debt
Net cashBiohaven Ltd. held $35 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Biohaven Ltd.: $2.2 B ÷ $12 M (30 Jun 2026) = 181.5.
What is Biohaven Ltd.'s return on equity?
Biohaven Ltd. lost 799.5% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
How much does Biohaven Ltd. owe compared with what it owns?
Biohaven Ltd. owes $0.97 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Does Biohaven Ltd. pay a dividend?
No. Biohaven Ltd. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.